[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371661-105":59,"doc-detail-371661-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ketone-drink-enhances-therapeutic-efficacy-in-prostate-cancer-by-targeting-ezh2","Ketone drink enhances therapeutic efficacy in prostate cancer by targeting EZH2","","EZH2, a lysine methyltransferase frequently upregulated in aggressive cancers, is implicated in cancer progression and metabolism, but its regulatory role in metabolic control remains incompletely defined. This study links EZH2 with HMGCS2, showing HMGCS2 inversely correlates with progression and prognosis in prostate and breast cancers. HMGCS2 is epigenetically repressed by EZH2 in vitro and in vivo, while restored EZH2 normalizes elevated HMGCS2, and HMGCS2 overexpression suppresses tumorigenesis. β-hydroxybutyrate (BHB), produced downstream of HMGCS2, impedes progression by targeting EZH2 through direct protein-compound interaction–mediated degradation. In therapy-resistant castration-resistant prostate cancer xenografts, BHB reduces tumor size and weight, and combining a ketone drink with enzalutamide and Tazemetostat further suppresses tumor progression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ketone-drink-enhances-therapeutic-efficacy-in-prostate-cancer-by-targeting-ezh2/371661/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ketone-drink-enhances-therapeutic-efficacy-in-prostate-cancer-by-targeting-ezh2/371661.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the relationship between EZH2 and HMGCS2 in this study?","Question",{"text":112,"@type":113},"The study reports a negative correlation between EZH2 and HMGCS2 in prostate and breast cancers. It also shows that EZH2 epigenetically represses HMGCS2 both in vitro and in vivo.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does β-hydroxybutyrate (BHB) affect prostate cancer progression?",{"text":117,"@type":113},"BHB, a downstream metabolite of HMGCS2, impedes prostate cancer progression by targeting EZH2. The mechanism involves direct protein-compound interaction-mediated protein degradation.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment outcomes were observed in therapy-resistant castration-resistant prostate cancer models?",{"text":121,"@type":113},"Administering BHB via a ketone drink dramatically reduced tumor size and weight in a patient-derived xenograft model. Combining the ketone drink with enzalutamide and Tazemetostat further suppressed tumor progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371661,1790598049,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":14,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Oncogenesis [www.nature.com/oncsis](www.nature.com/oncsis)  \nARTICLE OPEN   \nKetone drink enhances therapeutic efﬁcacy in prostate cancer by targeting EZH2  \nChaehyun Yum1, Richard A. Schaefer 1, Rui Wang 1, Ting-You Wang 1, Xiaotong Lu1,2, Qi Liu1, Yanan Ren1, Qingshu Meng 1  \n,  \nYongyong Yang1, Xin Zhang3, Yan Xiong3, Xufen Yu 3, Xiaoyu Zhang4,5,6,7,8, Jian Jin 3, Xuesen Dong 9,10, Yang Yi 1,4, Rendong Yang 1,4 ✉ and Qi Cao 1,4 ✉  \n© The Author(s) 2025  \n\n|  | It is well established that EZH2, a lysine methyltransferase, is upregulated in most aggressive cancers, highlighting the importance of EZH2 in cancer progression. Recent research has shown that metabolic reprogramming is pivotal in various biological processes, including cancer. Despite this, evidence of EZH2’s role in regulating cancer metabolism remains limited. Our study reveals a negative correlation between EZH2 and HMGCS2, a gene belonging to the HMG-CoA synthase, in prostate and breast cancers. Interestingly, HMGCS2 is inversely related to cancer progression and prognosis in these cancers. Furthermore, HMGCS2 isepigenetically repressed by EZH2 both in vitro and in vivo. Notably, restored EZH2 reduces the elevated HMGCS2 levels observed upon EZH2 depletion. Overexpression of HMGCS2 decreases tumorigenesis in both prostate and breast cancers. Additionally,β-hydroxybutyrate (BHB), a downstream metabolite of HMGCS2, impedes prostate cancer progression by targeting EZH2 via direct protein-compound interaction-mediated protein degradation. More importantly, the ketone drink of BHB administration dramatically reduces tumor size and weight in a therapy-resistant, castration-resistant prostate cancer patient-derived xenograft model. Combining a ketone drink with FDA-approved drugs enzalutamide and Tazemetostat further suppresses tumor progression. Overall, the EZH2-HMGCS2-BHB regulatory network plays a critical role in the progression of prostate cancer, and a ketone drink is a |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| novel therapeutic tool for patients with aggressive prostate cancer. |  |  |\n|  | Oncogenesis (2025)14:24; [https://doi.org/10.1038/s41389-025-00567-0](https://doi.org/10.1038/s41389-025-00567-0) |  |\n|  |  |  |\n\nINTRODUCTION  \nProstate cancer (PCa) is the second leading cause of cancer-related deaths in American men [1] . Despite advancements in treatment, some PCa cases progress to a hormone-refractory state known as castration-resistant prostate cancer (CRPC), which has a survival rate of only 1 to 2 years on average [2] . Enhancing survival rates necessitates a deeper understanding of the molecular mechanisms driving PCa development and its progression to CRPC. Both genetic and epigenetic factors play critical roles in PCa development. During tumor progression, epigenetic regulators reprogram normal and differentiated cells into undifferentiated cancer cells, promoting cell growth, invasion, and metastasis by upregulating oncogenes and downregulating tumor suppressors [3].  \nOne of the critical epigenetic regulators is the Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase that catalyzes the methylation of lysine 27 on histone H3 (H3K27) [4], leading to gene silencing and 3-D genome changes [5] . Overexpression of EZH2 is very common in most types of cancers, including prostate [6], breast [7], and melanoma [8], making it a potential target for  \ncancer therapy [4]. Currently, Tazemetostat has been approved by FDA for some patients with follicular lymphoma or epithelioid sarcoma [9] . Several EZH2 inhibitors are undergoing clinical trials for solid tumors [10] .  \nCancer cells often undergo metabolic reprogramming, adapting their metabolism to support rapid growth and survival in a nutrient-poor and hypoxic tumor microenvironment [11] . This reprogramming allows cancer cells to thrive by altering their glucose and lipid metabolism am","cbCaigS2vc9A9lL6","https://ap.wps.com/l/cbCaigS2vc9A9lL6","pdf",7126153,15,"English","# Introduction\n## EZH2 as an epigenetic regulator in prostate cancer\n## Metabolic reprogramming and cancer therapy potential","[{\"question\":\"What is the relationship between EZH2 and HMGCS2 in this study?\",\"answer\":\"The study reports a negative correlation between EZH2 and HMGCS2 in prostate and breast cancers. It also shows that EZH2 epigenetically represses HMGCS2 both in vitro and in vivo.\"},{\"question\":\"How does β-hydroxybutyrate (BHB) affect prostate cancer progression?\",\"answer\":\"BHB, a downstream metabolite of HMGCS2, impedes prostate cancer progression by targeting EZH2. The mechanism involves direct protein-compound interaction-mediated protein degradation.\"},{\"question\":\"What treatment outcomes were observed in therapy-resistant castration-resistant prostate cancer models?\",\"answer\":\"Administering BHB via a ketone drink dramatically reduced tumor size and weight in a patient-derived xenograft model. Combining the ketone drink with enzalutamide and Tazemetostat further suppressed tumor progression.\"}]","Ketone drink enhances therapeutic efficacy in prostate cancer by targeting EZH2 | PDF",1790192556,38,[147,151],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/a800d487bf3bd1a531423602a3a99927.webp",983,1306,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/67bc002c19b4b410954481e288b17e65.webp",982,1304]